HNRNPA2B1

Across TCGA pan-cancer cohorts, HNRNPA2B1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated HNRNPA2B1 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher HNRNPA2B1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HNRNPA2B1 expression acts as an unfavorable survival marker.

SCLC, LIHC, and CHOL are the cancer types where HNRNPA2B1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.055	0.708	<.001	36	view →
LIHC	DFS	Median	III,IV	0.076	0.360	.001	24	view →
CHOL	DFS	Median	All	0.045	0.486	.009	15	view →
HNSC	OS	Median	All	0.278	0.663	.015	12	view →
SKCM	OS	Median	All	0.245	0.781	.008	9	view →
ESCA	DFS	Median	All	0.089	0.507	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

HNRNPA2B1–SCLC (OS)

Open the SCLC breakdown →